[PDF][PDF] Development of soft sensors for online biomass prediction in production of hepatitis B vaccine
A Beiroti, SN Hosseini, D Norouzian… - … Res. Appl. Chem, 2022 - biointerfaceresearch.com
Neural networks can provide highly accurate and robust solutions for complex non-linear
kinetic like bioprocess reactions. It is applied as a soft sensor in the biotechnology industry …
kinetic like bioprocess reactions. It is applied as a soft sensor in the biotechnology industry …
Mapping the conformational epitope of a therapeutic monoclonal antibody against HBsAg by in vivo selection of HBV escape variants
CR Wu, HJ Kim, CP Sun, CY Chung, YY Lin… - …, 2022 - Wiley Online Library
Abstract Background and Aims Hepatitis B immunoglobulin (HBIG) has been routinely
applied in the liver transplantation setting to block HBV reinfection of grafts. However, new …
applied in the liver transplantation setting to block HBV reinfection of grafts. However, new …
Immune response induced by recombinant pres2/S-protein and a pres2-S-protein fused with a core 18-27 antigen fragment of hepatitis B virus compared to …
EG Parizad, AA Imani Fooladi, H Sedighian, E Behzadi… - Virus Genes, 2023 - Springer
Although comprehensive vaccination is the cornerstone of public health programs to control
hepatitis B virus (HBV) infections, 5% of people who receive the existing vaccine do not …
hepatitis B virus (HBV) infections, 5% of people who receive the existing vaccine do not …
[HTML][HTML] Comparison of Immune Response in Mice Immunized with Recombinant PreS2/S-C18-27 Protein Derived from Hepatitis B Virus with Commercial Vaccine
EG Parizad, AAI Fooladi, H Sedighian… - Iranian Journal of …, 2022 - ncbi.nlm.nih.gov
Methods: After the synthesis of PreS2/S genes and C18-27 peptide fragment in pET28a, the
recombinant protein was confirmed by Western blotting. The efficacy of the PreS2/S-C18-27 …
recombinant protein was confirmed by Western blotting. The efficacy of the PreS2/S-C18-27 …
[PDF][PDF] Immune Response in Mice Immunized with Recombinant PreS2/S-C18-27 Protein from Hepatitis B Virus Compared with Commercial Vaccine
E Gholami Parizad, AA Imani Fooladi… - Iranian journal of …, 2022 - ijp.iranpath.org
Background & Objective: The vaccine available to prevent Hepatitis B virus disease is
ineffective in 5% of people due to the use of HBsAg as a weak immunogen. In the present …
ineffective in 5% of people due to the use of HBsAg as a weak immunogen. In the present …
[HTML][HTML] Hepatitis B immunoglobulin inhibits the secretion of HBV via antigen-antibody precipitation in the multivesicular body
KC Yoon, S Seo, KW Lee, SC Oh, MY Park… - American Journal of …, 2023 - ncbi.nlm.nih.gov
Abstract Background and Aims: Although the main action of human hepatitis B
immunoglobulin (HBIG) is to neutralize hepatitis B virus surface antigen (HBsAg) in serum …
immunoglobulin (HBIG) is to neutralize hepatitis B virus surface antigen (HBsAg) in serum …